In re: Depo-Provera Products Liability Litigation

MDL No. 3140 · U.S. District Court, Northern District of Florida, Pensacola Division · Hon. M. Casey Rodgers · Mag. Judge Hope T. Cannon

At a glance
Controlling orders
46
Cases in roster
67
Certified JPML transfers
27
Counsel of record
90
Distinct firms
59
Calendar

Next critical dates

From the record
  • Jun 24, 2026 — Jun 26, 2026
    hearing
    Rule 702 (Daubert) Motions HearingGating event Date conflict
    Affects: all
    Conflict cite: Court site (FAQ page lists May 26-28, 2026 - dates conflict)
  • Jun 26, 2026
    cmc
    Case Management Conference
    Affects: all
    Source: PTO 28 (2026 CMC Schedule)
  • Jul 17, 2026
    cmc
    Case Management Conference
    Affects: all
    Source: PTO 28 (2026 CMC Schedule)
  • Aug 21, 2026
    cmc
    Case Management Conference
    Affects: all
    Source: PTO 28 (2026 CMC Schedule)
  • Sep 18, 2026
    cmc
    Case Management Conference
    Affects: all
    Source: PTO 28 (2026 CMC Schedule)
Context

Strategic posture

The MDL is in pretrial, with general-causation discovery ongoing. Plaintiffs allege long-term use of Depo-Provera (depot medroxyprogesterone acetate) causes intracranial meningioma and that defendants failed to warn.

The Rule 702 (Daubert) hearing on general causation is the gating event — its outcome will materially determine the trajectory of the entire MDL.

Defendants: Pfizer, Pharmacia & Upjohn, Pharmacia LLC, Greenstone LLC, Viatris Inc., Prasco LLC.

Docket activity

Recent orders

  • PTO#31
    Pretrial Order No. 31
    Leadership
    Mar 20, 2026
  • CMO#11
    Case Management Order No. 11
    Status
    Threshold Proof
    Mar 7, 2026
  • PTO#30
    Pretrial Order No. 30
    Merits
    Jan 27, 2026
  • CMO#10
    Case Management Order No. 10
    Merits
    Status
    Threshold Proof
    Jan 26, 2026
  • PTO#29
    Pretrial Order No. 29
    Leadership
    Jan 6, 2026
  • CMO#9
    Case Management Order No. 9
    Status
    Threshold Proof
    Dec 21, 2025